AbbVie M15-566
Back to Drug Development Trials
![]()
Drug Development Trials
About the AbbVie M15-566 trial
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer’s Disease (M15-566)
Additional info:
For further information, please contact our team on Ph: 08 9389 6433 or Email: aarfctd@alzheimersresearch.org.au
